- Home
- TPVG vs ANTX Comparison
TPVG vs ANTX Comparison
Compare TPVG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPVG | ANTX |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.2M | 170.6M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TPVG | ANTX |
|---|---|---|
| Price | $5.58 | $4.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.90 | $2.00 |
| AVG Volume (30 Days) | ★ 352.8K | 303.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 17.66% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ 1.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.48 | $1.00 |
| 52 Week High | $7.53 | $6.91 |
Technical Indicators
Market Signals| Indicator | TPVG | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 69.76 |
| Support Level | $5.41 | $1.06 |
| Resistance Level | $5.70 | $5.11 |
| Average True Range (ATR) | 0.19 | 0.37 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 84.17 | 85.25 |
Price Performance
Historical ComparisonAbout TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.